Spyre Therapeutics (SYRE) to Release Quarterly Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is expected to announce its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.73) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:00 PM ET.

Spyre Therapeutics (NASDAQ:SYRE) last released its earnings results on Tuesday, August 5th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.24. On average, analysts expect Spyre Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Spyre Therapeutics Trading Down 2.8%

Shares of Spyre Therapeutics stock opened at $23.78 on Tuesday. Spyre Therapeutics has a 52 week low of $10.91 and a 52 week high of $40.26. The stock has a market cap of $1.44 billion, a PE ratio of -6.99 and a beta of 2.90. The company’s 50-day moving average price is $18.54 and its two-hundred day moving average price is $16.70.

Insider Buying and Selling

In other Spyre Therapeutics news, CFO Scott L. Burrows sold 18,428 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $16.26, for a total value of $299,639.28. Following the transaction, the chief financial officer owned 97,994 shares of the company’s stock, valued at approximately $1,593,382.44. This represents a 15.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 15.43% of the company’s stock.

Institutional Investors Weigh In On Spyre Therapeutics

Several large investors have recently made changes to their positions in SYRE. BNP Paribas Financial Markets grew its position in Spyre Therapeutics by 300.0% in the second quarter. BNP Paribas Financial Markets now owns 223,320 shares of the company’s stock valued at $3,343,000 after purchasing an additional 167,487 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Spyre Therapeutics by 48.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 79,896 shares of the company’s stock worth $1,196,000 after buying an additional 25,995 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Spyre Therapeutics by 37.6% in the 2nd quarter. Invesco Ltd. now owns 34,680 shares of the company’s stock valued at $519,000 after acquiring an additional 9,473 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Spyre Therapeutics by 30.6% in the 2nd quarter. Rhumbline Advisers now owns 73,168 shares of the company’s stock valued at $1,095,000 after acquiring an additional 17,145 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Spyre Therapeutics by 13.8% in the second quarter. JPMorgan Chase & Co. now owns 47,279 shares of the company’s stock valued at $708,000 after acquiring an additional 5,723 shares during the last quarter. Institutional investors own 80.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SYRE. BTIG Research reissued a “buy” rating and issued a $70.00 price objective on shares of Spyre Therapeutics in a research note on Tuesday, September 16th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Spyre Therapeutics in a research report on Friday, September 26th. They issued a “buy” rating and a $43.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Spyre Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Spyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $65.00 price objective on shares of Spyre Therapeutics in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Spyre Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $52.50.

About Spyre Therapeutics

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).